While cancer vaccines have been in clinical trials for more than a decade, to date we have witnessed limited success with only one product (Provenge) approved by the FDA in 2010 to treat prostate cancer in men that have not received chemotherapy. However, the efforts of companies and researchers were not for nothing as lots of data have been collected that would help one day to create a cancer vaccine that would overcome past difficulties. In this article, we will focus on Heat Biologics (HTBX), a vaccine technology company that is developing various cellular therapeutic vaccines for a range of cancers and infectious diseases. While the company is at an earlier stage of development versus others in...
Heat Biologics: An Undervalued Cancer Vaccine Play That Leaves Considerable Room For Upside
Sep 30 2013, 15:22 | about: HTBX
BOOKMARKED / READ LATER
Added to your bookmarks on the Seeking Alpha homepage